H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Evolus (EOLS – Research Report) today and set a price target of $27.00.
Douglas Tsao has given his Buy rating due to a combination of factors including the anticipated growth and resilience of Evolus’s Jeuveau franchise, despite the economic uncertainties. Tsao notes that while the company has historically experienced modest seasonal variations, the increased scale of Jeuveau now aligns it with broader market trends, which were evident in the previous year’s market dynamics. Additionally, Evolus’s management has set expectations for Evolysse to contribute a small but significant portion of 2025’s sales, with a strong interest from accounts in the new technology.
Furthermore, Tsao highlights that Evolus has a track record of surpassing expectations and does not face the same regulatory risks as other biopharma companies. Although the current economic environment presents challenges, the toxin market has shown resilience in past economic downturns, which supports the Buy rating. The valuation is also supported by a price target based on a risk-adjusted revenue estimate, with a high probability of success for Jeuveau, reinforcing confidence in the company’s future profitability.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $22.00 price target.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EOLS in relation to earlier this year.